Medical marijuana program expanded in Connecticut

descConsumer Protection Commissioner Jonathan A. Harris announced May 18 that his agency will draft regulations that would add three new conditions to those that qualify for palliative use of medical marijuana in Connecticut. The conditions, amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), Fabry disease, and ulcerative colitis, were reviewed and voted upon by the Medical Marijuana Program’s Board of Physicians on April 22.
Earlier this year, the department began the process to adopt a regulation to add sickle cell disease, post laminectomy syndrome with chronic radiculopathy, and severe psoriasis and psoriatic arthritis to the list of 11 original conditions that qualify for palliative use of medical marijuana. These had been recommended by the Board of Physicians in January 2015.
The regulation review process for all conditions will include a hearing and public comment period before the proposed regulation is sent to the attorney general for review and then to the General Assembly’s Regulation Review Committee for the final vote needed to add the conditions to the regulations.
Current qualifying conditions include glaucoma, HIV/AIDS, Parkinson’s disease, multiple sclerosis, damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, epilepsy, cachexia (wasting syndrome), Crohn’s disease, and post-traumatic stress disorder (PTSD).
Qualifying patients must be a Connecticut resident, at least 18 years  old, and may not be an inmate confined in a correctional institute or facility under the supervision of the Connecticut Department of Corrections.
The closest medical marijuana dispensary to Wilton is located in Bethel.